Synthesis of Amides for Leishmaniasis Therapies
Session Number
3
Advisor(s)
Dr. John Thurmond, IMSA
Location
A121
Discipline
Chemistry
Start Date
15-4-2026 2:15 PM
End Date
15-4-2026 3:00 PM
Abstract
Leishmaniasis is a neglected tropical disease with limited treatment options due to toxicity, resistance, and accessibility barrier. To support leishmaniasis drug discovery efforts, our group will contribute to the Drugs for Neglected Diseases initiative (DNDi) Open Synthesis Network by synthesizing a novel benzoxazole amide derivative based on the benzoxazole amide lead series (e.g., DNDI0003202833). The targeted compounds will be prepared via amide bond formation between benzoxazol-2-amide and assigned carboxylic acid using EDCI with catalytic DMAP. Reaction progress will be monitored by thin-layer chromatography (TLC), followed by purification of the crude product by column chromatography. The final compound will be characterized by TLC and additional analytical methods (IR) to confirm identity
Synthesis of Amides for Leishmaniasis Therapies
A121
Leishmaniasis is a neglected tropical disease with limited treatment options due to toxicity, resistance, and accessibility barrier. To support leishmaniasis drug discovery efforts, our group will contribute to the Drugs for Neglected Diseases initiative (DNDi) Open Synthesis Network by synthesizing a novel benzoxazole amide derivative based on the benzoxazole amide lead series (e.g., DNDI0003202833). The targeted compounds will be prepared via amide bond formation between benzoxazol-2-amide and assigned carboxylic acid using EDCI with catalytic DMAP. Reaction progress will be monitored by thin-layer chromatography (TLC), followed by purification of the crude product by column chromatography. The final compound will be characterized by TLC and additional analytical methods (IR) to confirm identity